Bessemer Group
AUPH icon

Bessemer Group’s Aurinia Pharmaceuticals AUPH Stock Holding History

Bessemer Group’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3K Hold
188
– – ﹤0.01% 2303
2025
Q4 		$3K Hold
188
– – ﹤0.01% 2319
2025
Q3 		$2K Buy
+188
New +$2.05K ﹤0.01% 2291
2025
Q1 		– Sell
-215
Closed -$2K – 2437
2024
Q4 		$2K Hold
215
– – ﹤0.01% 2184
2024
Q3 		$2K Buy
+215
New +$1.33K ﹤0.01% 2167

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bessemer Group's AUPH Position: Q1 2026 in Review

Bessemer Group held its Aurinia Pharmaceuticals (AUPH) position steady in Q1 2026 at 188 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #2303.

Bessemer Group first reported a position in AUPH in Q3 2024 and has held it in 5 quarters since. 259 funds tracked by Wall St. Rank hold AUPH as of Q1 2026.

  • Bessemer Group held 188 shares of Aurinia Pharmaceuticals worth $3K as of Q1 2026.
  • Bessemer Group left its Aurinia Pharmaceuticals share count unchanged in Q1 2026.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Bessemer Group's portfolio in Q1 2026, its #2303 holding.
  • Bessemer Group first reported a position in Aurinia Pharmaceuticals in Q3 2024 and has held it in 5 quarters since.
  • 259 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2026.

Based on Bessemer Group's 13F filing for Q1 2026, filed 6 May 2026.